Study shows long-term safety and effectiveness of MiStent SES


eMediNexus    29 December 2017

Five-year outcomes from the DESSOLVE I and II trials published December 26, 2017 in the journal EuroIntervention show the long-term safety and effectiveness of a sirolimus-eluting stent (MiStent SES) with a bioabsorbable coating with low rates of five-year major adverse cardiac events (MACE), target lesion failure (TLF) and target vessel failure (TVF). No stent thrombosis was reported with the MiStent in both the trials.

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.